Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 728

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 728
---
 TuHURA
special meeting of stockholders. If you request any documents from us, we will mail them to you by first class mail, or another equally prompt means.

Kineta

Kineta files reports, proxy
statements and other information with the SEC as required by the Exchange Act. The SEC maintains a website that contains reports, proxy statements and other information about Kineta. You can read Kineta’s SEC filings, including this joint proxy
statement/prospectus, over the Internet at the SEC’s website at http://www.sec.gov. The reports and other information filed by Kineta with the SEC are also available at Kineta’s website, which is http://www.kinetabio.com. Information on
Kineta’s website is not part of this joint proxy statement/prospectus.

495

If you would like additional copies of this joint proxy statement/prospectus or if you have
questions about the Merger or the proposals to be presented at the Kineta special meeting, you should contact us by telephone or in writing:

Kineta, Inc.

7683 SE 27th Street,
Suite 481

Mercer Island, WA 98040

Attention: Corporate Secretary

Telephone: (206) 378-0400

If you are a stockholder of Kineta and would like to request documents, please do so by June 16, 2025 to receive them before the Kineta
special meeting of stockholders. If you request any documents from us, we will mail them to you by first class mail, or another equally prompt means.

496

INDEX TO FINANCIAL STATEMENTS

| TUHURA (F/K/A KINTARA THERAPEUTICS, INC.) FINANCIAL STATEMENTS                    
 Report of Independent Registered Public Accounting Firm                           
 Consolidated Balance Sheets as of June 30, 2024 and 2023                          
 Consolidated Statements of Operations for the Years Ended June 30, 2024 and 2023  |     | F-2  
 F-4  
 F-5  |
|:----------------------------------------------------------------------------------|:----|:-----|
| Consolidated Statements of Stockholders’ Equity (Deficit) for the Years Ended     
 June 30, 2024 and 2023                                                            |     | F-6  |
| Consolidated Statements of Cash Flows for the Years Ended June 30, 2024 and 2023  |     | F-7  |
| Notes to the Consolidated Financial Statements                                    |     | F-